Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
When Christine Corrado interviews Dania Scott about the anticipated $675 million annual 2027 revenue Tetra's CBD-based cancer pain relief prescription drug QIXLEEF, she asks, "So in order to get you there, would you need a potential partner?" Dania Scott replies some very telling and positive things, "Absolutely. We're looking for a potential partner. Our ideal partner would have existing pharmaceutical commercial execution capabilities in the United States with an understanding of the pain and/or cancer landscape, ideally both; reimbursement insights, patients and healthcare providers engagement."

Note an important fact not to miss about the $675 million expected revenue in 2027 for QIXLEEF is the $675 million is JUST THE U.S. SALES figures, and they are already moving QIXLEEF's alter ego ENJOUCA into the UK and the EU (Germany first). According to the Chief Commercial Officer, Steeve Neron, the UK and Germany are accessible to Tetra, when the new ENJOUCA domains for the UK and EU were brought up: "UK and Germany are indeed more opened to Medical Cannabis in other words yes ENJOUCA could be launched in these jurisdictions in pre launch to QIXLEEF and in these two countries we could maintain both brands." They are all serious about having EUROPEAN QIXLEEF SALES way up there like for the U.S. cancer pain market, also. Along these lines their top person from CANOPY GROWTH, Dania Scott, Sr. Vice President, Commercial Strategy, who is very familiar with both the Tetra drug products and the Canopy's Mighty Medic vaporizer that goes with their inhaled cannabis products, and which is certified as a Class II medical device, spoke publicly that she considers this a conservative projection for the U.S. sales figures in 2027. She should know. So, what share of the global market would their share of the U.S. market give them in 2027 in that scenario? Over 8% of the U.S. cancer pain market.

In 2025 GLOBAL SALES of cancer pain market is $7,545 Million.
In 2027 GLOBAL SALES from a CAGR of 4.5% is $8,239 million.
Tetra's 2027 US SALES of $675 Million is 8.2% of 2027 GLOBAL SALES. FOR US QIXLEEF SALES ONLY!

The global cancer pain market (opioids, non-opioids, and nerve blockers) generated about $5.3 billion in 2017, and is projected to reach over $7.5 billion by 2025, growing at a CAGR of 4.5% from 2018 to 2025. The opioids (morphine) segment holds the largest share in 2019, owning more than half of the market and it is expected to continue this dominance throughout the period. The opioid segment has registered a very fast CAGR during this period so far. With doctors and patients scrambling for a safer alternative to morphine and other deadly opioids, Tetra Bio-Pharma's QIXLEEF is going to be one of the main beneficiaries of the move out of opioids into cannabinoids. According to Ms. Scott,

The opioids segment held the largest share in 2018, contributing more than half of the market and is expected to continue its dominance throughout the study period. In addition, the segment is estimated to register the fastest CAGR of 5.0% during the forecast period.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.